Cerebral infarction
Drug research and approvals for cerebral infarction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 156 studies of cerebral infarction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 156
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A…NCT07935408 · Not reported · Second Affiliated Hospital of Soochow University · starts Mar 1, 2026
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNCT07933692 · Phase 4 · Shandong Provincial Hospital · starts Oct 1, 2021
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisNCT07932639 · Phase 4 · Second Affiliated Hospital of Soochow University · starts Mar 21, 2026
- Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA OcclusionNCT07927569 · Not reported · Qianfoshan Hospital · starts Mar 21, 2024
- Effects of Mirror Therapy and Motor Imagery on Upper Limb Motor Functions in Middle Cerebral Artery StrokeNCT07902284 · Not applicable · Lahore University of Biological and Applied Sciences · starts Aug 15, 2026
- Metabolomics in Subarachnoid HemorrhageNCT07865182 · Not reported · Unidade Local de Saude Sao Jose · starts May 1, 2025
- Biomarkers as Prognostic Factors of Silent, Cerebral Infarctions in Patients Undergoing High-thromboembolic-risk…NCT07844850 · Not reported · Aristotle University Of Thessaloniki · starts Jun 10, 2025
- SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel OcclusionsNCT07843797 · Not applicable · Hospital Universitari Vall d'Hebron Research Institute · starts Nov 1, 2026
Phase 3 6
- AspirinCyclooxygenase inhibitor
- CilostazolPhosphodiesterase 3A inhibitor
- SarpogrelateSerotonin 2a (5-HT2a) receptor antagonist
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- AlteplaseTissue-type plasminogen activator exogenous protein
- Citicoline
Phase 2 5
- VorapaxarProteinase-activated receptor 1 antagonist
- TenecteplaseTissue-type plasminogen activator exogenous protein
- AmantadineGlutamate [NMDA] receptor antagonist
- Albumin humanBilirubin sequestering agent
- Kallidinogenase
Phase 1 or earlier 1
- AtorvastatinHMG-CoA reductase inhibitor
How its trials ended
922 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 172 whose ending is known, 36% met their primary endpoint, 14% missed it and 50% stopped early.
- Completed, result not reported29532%
- Ongoing27330%
- Status unknown18220%
- Met its primary endpoint627%
- Stopped: other or unclear495%
- Missed its primary endpoint243%
- Stopped: enrollment or feasibility222%
- Stopped: lack of efficacy91%
- Stopped: sponsor or business decision4<1%
- Stopped: safety1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA